Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GPCR |
---|---|---|
09:32 ET | 11087 | 41.775 |
09:34 ET | 1800 | 41.7981 |
09:36 ET | 600 | 42.1476 |
09:38 ET | 1639 | 42.81 |
09:39 ET | 300 | 42.26 |
09:41 ET | 3100 | 42.9 |
09:43 ET | 300 | 42.75 |
09:45 ET | 7200 | 43.58 |
09:48 ET | 2176 | 43.28 |
09:50 ET | 3379 | 43.38 |
09:52 ET | 6985 | 43.4508 |
09:54 ET | 3696 | 43.32 |
09:56 ET | 1220 | 43.375 |
09:57 ET | 2000 | 43.375 |
09:59 ET | 1941 | 43.98 |
10:01 ET | 13472 | 44.27 |
10:03 ET | 900 | 44.49 |
10:06 ET | 1397 | 44.545 |
10:08 ET | 13613 | 44.21 |
10:10 ET | 10168 | 43.65 |
10:12 ET | 2668 | 43.605 |
10:14 ET | 1900 | 43.72 |
10:15 ET | 915 | 43.69 |
10:17 ET | 7210 | 44.1077 |
10:19 ET | 8195 | 43.87 |
10:21 ET | 1506 | 43.72 |
10:24 ET | 1460 | 43.935 |
10:26 ET | 1500 | 43.89 |
10:28 ET | 3962 | 43.765 |
10:30 ET | 5318 | 43.715 |
10:32 ET | 1400 | 43.675 |
10:33 ET | 35439 | 42.485 |
10:35 ET | 5213 | 42.6 |
10:37 ET | 300 | 42.495 |
10:39 ET | 1300 | 42.365 |
10:42 ET | 2152 | 42.26 |
10:44 ET | 1400 | 42.165 |
10:46 ET | 228 | 42.0199 |
10:48 ET | 100 | 42.07 |
10:50 ET | 2880 | 41.76 |
10:51 ET | 1300 | 41.845 |
10:53 ET | 3741 | 41.6 |
10:55 ET | 10800 | 41.95 |
10:57 ET | 3819 | 42.28 |
11:00 ET | 4972 | 42.29 |
11:02 ET | 5299 | 42.44 |
11:04 ET | 400 | 42.47 |
11:06 ET | 1100 | 42.51 |
11:08 ET | 5625 | 42.41 |
11:09 ET | 1150 | 42.4 |
11:11 ET | 1000 | 42.34 |
11:13 ET | 721 | 42.38 |
11:15 ET | 300 | 42.27 |
11:18 ET | 2871 | 42.55 |
11:20 ET | 3013 | 42.66 |
11:22 ET | 800 | 42.475 |
11:24 ET | 900 | 42.475 |
11:26 ET | 550 | 42.4 |
11:27 ET | 1500 | 42.455 |
11:29 ET | 4746 | 42.8 |
11:31 ET | 1550 | 42.87 |
11:33 ET | 1100 | 42.94 |
11:36 ET | 800 | 42.94 |
11:38 ET | 100 | 42.83 |
11:42 ET | 1708 | 42.81 |
11:44 ET | 1300 | 42.89 |
11:45 ET | 300 | 42.9194 |
11:47 ET | 1500 | 42.88 |
11:49 ET | 500 | 42.94 |
11:51 ET | 5818 | 43.125 |
11:54 ET | 100 | 43.17 |
11:56 ET | 330 | 43.265 |
11:58 ET | 1200 | 43.255 |
12:00 ET | 100 | 43.25 |
12:02 ET | 400 | 43.21 |
12:03 ET | 900 | 43.12 |
12:05 ET | 200 | 43.11 |
12:07 ET | 100 | 43.07 |
12:09 ET | 400 | 43.155 |
12:12 ET | 3735 | 42.82 |
12:14 ET | 737 | 42.81 |
12:16 ET | 250 | 42.8271 |
12:18 ET | 100 | 42.9 |
12:20 ET | 100 | 43 |
12:21 ET | 100 | 42.91 |
12:23 ET | 2619 | 42.92 |
12:25 ET | 100 | 42.99 |
12:27 ET | 2500 | 43 |
12:32 ET | 800 | 42.87 |
12:36 ET | 1163 | 42.7 |
12:38 ET | 687 | 42.7698 |
12:39 ET | 600 | 42.94 |
12:43 ET | 592 | 42.995 |
12:45 ET | 1600 | 43.005 |
12:48 ET | 112 | 43.005 |
12:50 ET | 706 | 43 |
12:52 ET | 500 | 42.975 |
12:56 ET | 1000 | 42.91 |
12:57 ET | 641 | 42.8075 |
12:59 ET | 400 | 42.84 |
01:01 ET | 100 | 42.845 |
01:03 ET | 200 | 42.845 |
01:06 ET | 100 | 42.888 |
01:10 ET | 100 | 42.84 |
01:14 ET | 400 | 42.88 |
01:15 ET | 1425 | 42.75 |
01:17 ET | 3811 | 42.625 |
01:19 ET | 600 | 42.515 |
01:21 ET | 400 | 42.195 |
01:24 ET | 840 | 42.235 |
01:26 ET | 200 | 42.32 |
01:28 ET | 200 | 42.34 |
01:30 ET | 385 | 42.33 |
01:32 ET | 600 | 42.34 |
01:35 ET | 500 | 42.32 |
01:39 ET | 925 | 42.455 |
01:42 ET | 250 | 42.4414 |
01:44 ET | 1700 | 42.365 |
01:46 ET | 500 | 42.52 |
01:48 ET | 100 | 42.52 |
01:50 ET | 1700 | 42.39 |
01:51 ET | 296 | 42.485 |
01:53 ET | 550 | 42.47 |
01:57 ET | 841 | 42.515 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Structure Therapeutics Inc | 2.4B | -19.0x | --- |
Edgewise Therapeutics Inc | 2.4B | -17.0x | --- |
CG Oncology Inc | 2.4B | -31.2x | --- |
SpringWorks Therapeutics Inc | 2.4B | -7.1x | --- |
Celldex Therapeutics Inc | 2.4B | -12.1x | --- |
Vera Therapeutics Inc | 2.5B | -20.6x | --- |
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.24 |
Book Value | $9.76 |
P/E Ratio | -19.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.